TNF and COVID-19–associated multisystem inflammatory syndrome in children: Fortunately, patients with KD and MIS-C both improve with IVIG and corticosteroid therapy, and in case of failure a second dose of IVIG or TNF-α or IL-1 inhibitor can be considered, although the efficacy of any therapy for MIS-C is evolving and yet unproven [39]